ArticleHepatology international2026
Characteristic geoepidemiology and phenotype of autoimmune hepatitis: an 8-year population-based study in Taiwan.
Article in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsData on the geoepidemiology and phenotype of autoimmune hepatitis (AIH) among individuals in Asia are limited.
methodsAIH patients were identified from the Taiwan National Health Insurance administrative database (n=24,867,461) with the ICD-10 CM code K75.4.
resultsA total of 8909 AIH patients (females, n=6018) were included. The average age- and sex-adjusted prevalence (2016-2023) and incidence rates (2017-2023) were 20.505 per 100,000 population and 4.739 per 100,000 population per year, respectively. The overall annual percentage changes for prevalence and incidence were 25.56% (p<0.0001) and 4.85% (p<0.0001), respectively. Compared with AIH patients in southern Taiwan, AIH patients in northern Taiwan accounted for the majority (72.70%) and were younger at diagnosis (54.17 vs. 55.62 years, p=0.0011). The 8-year liver cirrhosis (LC), hepatocellular carcinoma (HCC), liver transplantation (LT), mortality and LT-free mortality cumulative incidence rates (CIRs) were 19.21%, 3.78%, 1.48%, 21.12% and 20.93%, respectively. The 8-year CIRs for hypertension, hyperlipidemia and diabetes were 44.77%, 46.84%, and 32.24%, respectively, and these diseases were the most common extrahepatic diseases. Lower hepatic and cardiometabolic complications and mortality but higher autoimmune complication CIRs were detected in northern than in southern Taiwan AIH patients. Higher hepatic and autoimmune complications but lower cardiometabolic complications and mortality CIRs were detected in female than in male AIH patients. Sex, age, residency, income, hepatic complications, diabetes and hyperlipidemia were associated with LC; sex, age, LC, ascites and diabetes were associated with HCC; and sex, age, residency, income, diabetes, hepatic complications, hyperlipidemia, systemic lupus erythematosus, thyroid diseases, systemic sclerosis and non-HCC cancers were associated with LT-free mortality.
conclusionIn Taiwan, the prevalence and incidence rates of AIH have increased over time. Care tailored to the patient's sex, age, residency, income and different complications is needed to improve outcomes.
Indexed as
Identifiers
42848155What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.